Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Caveolin-1 as a potential high-risk prostate cancer biomarker

J. Gumulec, J. Sochor, M. Hlavna, M. Sztalmachova, S. Krizkova, P. Babula, R. Hrabec, A. Rovny, V. Adam, T. Eckschlager, R. Kizek, M. Masarik

. 2012 ; 27 (3) : 831-841.

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12034835

Grantová podpora
NS10200 MZ0 CEP - Centrální evidence projektů

Current diagnostic techniques of prostate cancer cannot efficiently distinguish the latent and low-risk forms from the high-risk significant forms of prostate cancer. Caveolin-1 (Cav-1), except other functions, plays an important role in cell transformation and the process of tumorigenesis. Furthermore, Cav-1 is involved in metastatic processes. It has also been shown that Cav-1 expression is induced under stress conditions, such as oxidative stress. The present study focused on the determination of prognostic markers of aggressive (high-grade) forms of prostate cancer. We determined serum Cav-1 and serum markers of antioxidant activity-glutathione (GSH), 2,2-diphenyl-1-picrylhydrazyl (DPPH), Trolox equivalent antioxidant capacity (TEAC), ferric-reducing antioxidant power (FRAP), N,N-dimethyl-1,4-diaminobenzene (DMPD), free radicals method (FRK) and blue chromium peroxide (Cro) in 97 serum samples (82 prostate cancer patients and 15 controls). We found insignificant differences in Cav-1 between the sera of patients and controls (5.69 in the cancer group vs. 5.42 ng/ml in the control group). However, we found a significant (p<0.004) 2.8-fold elevation of Cav-1 in high tumour stages (TNM T4) compared to lower stages and a significant positive association with histological grading (r=0.29, p=0.028). We also found that in patients with high serum Cav-1 the antioxidant capacity of the body is reduced. These findings indicate that Cav-1 may be an interesting tool for the prediction of disease burden.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12034835
003      
CZ-PrNML
005      
20141105150135.0
007      
ta
008      
121023s2012 gr f 000 0|eng||
009      
AR
024    7_
$a 10.3892/or.2011.1587 $2 doi
035    __
$a (PubMed)22159333
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Gumulec, Jaromír, $d 1963- $7 xx0054104 $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, and Department of Urology, St. Anne's University Hospital Brno, CZ-625 00 Brno, Czech Republic.
245    10
$a Caveolin-1 as a potential high-risk prostate cancer biomarker / $c J. Gumulec, J. Sochor, M. Hlavna, M. Sztalmachova, S. Krizkova, P. Babula, R. Hrabec, A. Rovny, V. Adam, T. Eckschlager, R. Kizek, M. Masarik
520    9_
$a Current diagnostic techniques of prostate cancer cannot efficiently distinguish the latent and low-risk forms from the high-risk significant forms of prostate cancer. Caveolin-1 (Cav-1), except other functions, plays an important role in cell transformation and the process of tumorigenesis. Furthermore, Cav-1 is involved in metastatic processes. It has also been shown that Cav-1 expression is induced under stress conditions, such as oxidative stress. The present study focused on the determination of prognostic markers of aggressive (high-grade) forms of prostate cancer. We determined serum Cav-1 and serum markers of antioxidant activity-glutathione (GSH), 2,2-diphenyl-1-picrylhydrazyl (DPPH), Trolox equivalent antioxidant capacity (TEAC), ferric-reducing antioxidant power (FRAP), N,N-dimethyl-1,4-diaminobenzene (DMPD), free radicals method (FRK) and blue chromium peroxide (Cro) in 97 serum samples (82 prostate cancer patients and 15 controls). We found insignificant differences in Cav-1 between the sera of patients and controls (5.69 in the cancer group vs. 5.42 ng/ml in the control group). However, we found a significant (p<0.004) 2.8-fold elevation of Cav-1 in high tumour stages (TNM T4) compared to lower stages and a significant positive association with histological grading (r=0.29, p=0.028). We also found that in patients with high serum Cav-1 the antioxidant capacity of the body is reduced. These findings indicate that Cav-1 may be an interesting tool for the prediction of disease burden.
650    _2
$a senioři $7 D000368
650    _2
$a antioxidancia $x metabolismus $7 D000975
650    _2
$a bifenylové sloučeniny $x krev $7 D001713
650    _2
$a kaveolin 1 $x krev $7 D051242
650    _2
$a chromany (dihydrobenzopyrany) $x krev $x metabolismus $7 D002839
650    _2
$a sloučeniny chromu $x krev $7 D017608
650    _2
$a volné radikály $x krev $7 D005609
650    _2
$a glutathion $x krev $7 D005978
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a oxidační stres $7 D018384
650    _2
$a peroxidy $x krev $7 D010545
650    _2
$a pikráty $x krev $7 D010851
650    _2
$a nádory prostaty $x krev $7 D011471
650    _2
$a nádorové biomarkery $x krev $7 D014408
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1#
$a Sochor, J. $7 _AN063450
700    1#
$a Hlavna, Marian. $7 _AN049680
700    1_
$a Sztalmachová, Markéta $7 xx0146032
700    1_
$a Křížková, Soňa, $d 1981- $7 xx0105812
700    1_
$a Babula, Petr, $d 1979- $7 xx0074947
700    1_
$a Hrabec, Roman
700    1_
$a Rovný, Arne, $d -2012 $7 xx0106969
700    1_
$a Adam, Vojtěch, $d 1982- $7 xx0064599
700    1_
$a Eckschlager, Tomáš, $d 1956- $7 jn20000400613
700    1_
$a Kizek, René, $d 1972- $7 jn20001005291
700    1_
$a Masařík, Michal $7 xx0104244
773    0_
$w MED00179060 $t Oncology reports $x 1791-2431 $g Roč. 27, č. 3 (2012), s. 831-841
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22159333 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20121023 $b ABA008
991    __
$a 20141105150143 $b ABA008
999    __
$a ok $b bmc $g 956845 $s 792332
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 27 $c 3 $d 831-841 $i 1791-2431 $m Oncology reports $n Oncol Rep $x MED00179060
GRA    __
$a NS10200 $p MZ0
LZP    __
$a Pubmed-20121023

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...